World Psychiatric Association Pharmacopsychiatry Section statement on comparative effectiveness of antipsychotics in the treatment of schizophrenia, Schizophrenia Research, vol.100, issue.1-3, pp.1-320, 2008. ,
DOI : 10.1016/j.schres.2007.11.033
Antipsychotic Combinations vs Monotherapy in Schizophrenia: A Meta-analysis of Randomized Controlled Trials, Schizophrenia Bulletin, vol.35, issue.2, pp.443-457, 2009. ,
DOI : 10.1093/schbul/sbn018
Does the addition of a second antipsychotic drug improve clozapine treatment? Schizophr Bull, pp.458-468, 2009. ,
Trends in the pharmacological treatment of patients with schizophrenia over a 12 year observation period, Schizophrenia Research, vol.77, issue.1, pp.25-34, 2005. ,
DOI : 10.1016/j.schres.2005.01.015
Clinical features and therapeutic management of patients admitted to Italian acute hospital psychiatric units: the PERSEO (Psychiatric EmeRgency Study and EpidemiOlogy) survey, Annals of General Psychiatry, vol.6, issue.1, p.29, 2007. ,
DOI : 10.1186/1744-859X-6-29
Antipsychotic monotherapy and polypharmacy in the naturalistic treatment of schizophrenia with atypical antipsychotics, BMC Psychiatry, vol.31, issue.1, p.26, 2005. ,
DOI : 10.1097/01.jcp.0000117422.05703.ae
Antipsychotic medication coprescribing in a large state hospital system. Pharmacoepidemiology and drug safety, pp.41-48, 2003. ,
Practice regarding antipsychotic therapy: A cross-sectional survey in two Norwegian hospitals, Nordic Journal of Psychiatry, vol.55, issue.4, pp.313-317, 2004. ,
DOI : 10.1080/08039480410005837
Treatment of schizophrenia with antipsychotics in Norwegian emergency wards, a cross-sectional national study, BMC Psychiatry, vol.112, issue.1, p.24, 2009. ,
DOI : 10.1111/j.1600-0447.2005.00547.x
Adherence to Treatment With Antipsychotic Medication and Health Care Costs Among Medicaid Beneficiaries With Schizophrenia, American Journal of Psychiatry, vol.161, issue.4, pp.692-699, 2004. ,
DOI : 10.1176/appi.ajp.161.4.692
Schizophrenia, neuroleptic medication and mortality, The British Journal of Psychiatry, vol.188, issue.2, pp.122-127, 2006. ,
DOI : 10.1192/bjp.188.2.122
Antipsychotic Polypharmacy and Risk of Death From Natural Causes in Patients With Schizophrenia, The Journal of Clinical Psychiatry, vol.71, issue.02, pp.71103-108, 2010. ,
DOI : 10.4088/JCP.08m04818yel
Prospective analysis of premature mortality in schizophrenia in relation to health service engagement: a 7.5-year study within an epidemiologically complete, homogeneous population in rural Ireland, Psychiatry Research, vol.117, issue.2, pp.127-135, 2003. ,
DOI : 10.1016/S0165-1781(03)00002-7
11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study), The Lancet, vol.374, issue.9690, pp.374620-627, 2009. ,
DOI : 10.1016/S0140-6736(09)60742-X
Beyond the "Hype" on the Association Between Metabolic Syndrome and Atypical Antipsychotics, Journal of Clinical Psychopharmacology, vol.28, issue.2, pp.1471-244, 2011. ,
DOI : 10.1097/JCP.0b013e318166f533
Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group, pp.2265-2281, 1998. ,
The European Schizophrenia Cohort (EuroSC): a naturalistic prognostic and economic study. Social psychiatry and psychiatric epidemiology, pp.40707-717, 2005. ,
A prospective study of Quality of life in schizophrenia in three European countries, Schizophrenia Research, vol.93, issue.1-3, pp.1-3194, 2007. ,
DOI : 10.1016/j.schres.2007.03.005
Direct medical mental health care costs of schizophrenia in France, Germany and the United Kingdom -findings from the European Schizophrenia Cohort (EuroSC) Eur Psychiatry, pp.216-224, 2009. ,
Correlates of Subjective Quality of Life in People With Schizophrenia, The Journal of Nervous and Mental Disease, vol.196, issue.2, pp.87-94, 2008. ,
DOI : 10.1097/NMD.0b013e318162aa9c
Predictors of employment status change over 2 years in people with schizophrenia living in Europe. Epidemiologia e psichiatria sociale, pp.344-351, 2009. ,
Burden on caregivers of people with schizophrenia: comparison between Germany and Britain, The British Journal of Psychiatry, vol.190, issue.4, pp.333-338, 2007. ,
DOI : 10.1192/bjp.bp.106.025353
Residential area and social contacts in schizophrenia. Results from the European Schizophrenia Cohort (EuroSC) Social psychiatry and psychiatric epidemiology, pp.42617-622, 2007. ,
Urban residence, victimhood and the appraisal of personal safety in people with schizophrenia: results from the European Schizophrenia Cohort (EuroSC), Psychological Medicine, vol.188, issue.04, pp.591-597, 2008. ,
DOI : 10.1093/schbul/sbi060
The current state of adult mental health care in France, European Archives of Psychiatry and Clinical Neuroscience, vol.183, issue.suppl 410, pp.64-70, 2007. ,
DOI : 10.1007/s00406-006-0693-z
Significance of positive and negative syndromes in chronic schizophrenia, The British Journal of Psychiatry, vol.149, issue.4, pp.439-448, 1986. ,
DOI : 10.1192/bjp.149.4.439
Validity and reliability of the French-language version of the Positive and Negative Syndrome Scale (PANSS), Acta Psychiatrica Scandinavica, vol.158, issue.3, pp.237-243, 1999. ,
DOI : 10.1016/0920-9964(90)90005-R
The Global Assessment Scale, Archives of General Psychiatry, vol.33, issue.6, pp.766-771, 1976. ,
DOI : 10.1001/archpsyc.1976.01770060086012
Global Assessment of Relational Functioning Scale (GARF): II. Reliability and Validity in a Sample of Families of Bipolar Patients, Family Process, vol.129, issue.2, pp.175-189, 1996. ,
DOI : 10.1111/j.1545-5300.1989.00169.x
Revising axis V for DSM-IV: a review of measures of social functioning, Am J Psychiatry, vol.149, issue.9, pp.1148-1156, 1992. ,
Assessing depression in schizophrenia: the Calgary Depression Scale, Br J Psychiatry, vol.22, pp.39-44, 1993. ,
Evaluation of depression in schizophrenia: psychometric properties of a French version of the Calgary Depression Scale, Psychiatry Research, vol.89, issue.2, pp.123-132, 1999. ,
DOI : 10.1016/S0165-1781(99)00097-9
A RATING SCALE FOR EXTRAPYRAMIDAL SIDE EFFECTS, Acta Psychiatrica Scandinavica, vol.45, issue.S212, pp.11-19, 1970. ,
DOI : 10.1111/j.1600-0447.1970.tb02066.x
A rating scale for drug-induced akathisia, The British Journal of Psychiatry, vol.154, issue.5, pp.672-676, 1989. ,
DOI : 10.1192/bjp.154.5.672
Assessment of tardive dyskinesia using the Abnormal Involuntary Movement Scale. The Journal of nervous and mental disease, pp.353-357, 1985. ,
Rating of Medication Influences (ROMI) Scale in Schizophrenia, Schizophrenia Bulletin, vol.20, issue.2, pp.297-310, 1994. ,
DOI : 10.1093/schbul/20.2.297
The French SF-36 Health Survey, Journal of Clinical Epidemiology, vol.51, issue.11, pp.511013-1023, 1998. ,
DOI : 10.1016/S0895-4356(98)00093-6
The MOS 36-ltem Short-Form Health Survey (SF-36), Medical Care, vol.30, issue.6, pp.473-483, 1992. ,
DOI : 10.1097/00005650-199206000-00002
What is relapse in schizophrenia?, International Clinical Psychopharmacology, vol.9, issue.5, pp.5-9, 1995. ,
DOI : 10.1097/00004850-199501005-00002
Methodological Issues in Current Antipsychotic Drug Trials, Schizophrenia Bulletin, vol.34, issue.2, pp.275-285, 2008. ,
DOI : 10.1093/schbul/sbm159
Conditioning on the propensity score can result in biased estimation of common measures of treatment effect: a Monte Carlo study, Statistics in Medicine, vol.137, issue.4, pp.754-768, 2007. ,
DOI : 10.1002/sim.2618
Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophrenia research, pp.91-100, 2007. ,
Comparison of Logistic Regression versus Propensity Score When the Number of Events Is Low and There Are Multiple Confounders, American Journal of Epidemiology, vol.158, issue.3, pp.280-287, 2003. ,
DOI : 10.1093/aje/kwg115
Age at onset and cognition in schizophrenia: meta-analysis, The British Journal of Psychiatry, vol.195, issue.4, pp.286-293, 2009. ,
DOI : 10.1192/bjp.bp.108.060723
Use of combinations of antipsychotics: McLean Hospital inpatients, 2002, Human Psychopharmacology: Clinical and Experimental, vol.64, issue.7, pp.485-492, 2002. ,
DOI : 10.1002/hup.719
Long-Term Antipsychotic Polypharmacy in the VA Health System: Patient Characteristics and Treatment Patterns, Psychiatric Services, vol.58, issue.4, pp.489-495, 2007. ,
DOI : 10.1176/ps.2007.58.4.489
Clinicians' reasons for antipsychotic coprescribing. The Journal of clinical psychiatry, pp.1597-1600, 2004. ,
Combination Antipsychotic Therapy in Clinical Practice, Psychiatric Services, vol.54, issue.1, pp.55-59, 2003. ,
DOI : 10.1176/appi.ps.54.1.55
National Trends in Psychotropic Medication Polypharmacy in Office-Based Psychiatry, Archives of General Psychiatry, vol.67, issue.1, pp.26-36 ,
DOI : 10.1001/archgenpsychiatry.2009.175
The burden of depressive symptoms in the long-term treatment of patients with schizophrenia. Schizophrenia research, pp.1-3186, 2007. ,
Monotherapy Versus Polypharmacy for Hospitalized Psychiatric Patients, American Journal of Psychiatry, vol.162, issue.3, pp.631-632, 2005. ,
DOI : 10.1176/appi.ajp.162.3.631
Antipsychotic Polypharmacy: A Survey of Discharge Prescriptions from a Tertiary Care Psychiatric Institution, The Canadian Journal of Psychiatry, vol.133, issue.4, pp.334-339, 2001. ,
DOI : 10.1001/archpsyc.1988.01800330013001
The expert consensus guideline series: adherence problems in patients with serious and persistent mental illness. The Journal of clinical psychiatry, pp.1-46, 2009. ,
Estimating Causal Effects from Large Data Sets Using Propensity Scores, Annals of Internal Medicine, vol.127, issue.8_Part_2, pp.757-763, 1997. ,
DOI : 10.7326/0003-4819-127-8_Part_2-199710151-00064